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Abstract 1 
Breed-specific and broader cohort studies have shown behavioural changes in dogs 2 
following the onset of idiopathic epilepsy (IE). A cross-sectional, case-control questionnaire 3 
study was carried out to strengthen this body of evidence. Owners of eight breeds of dog 4 
completed an online questionnaire about their dogs’ behaviour; once for control dogs and 5 
twice for dogs with IE, for both pre- and post-IE onset behaviour. Ninety-six (24.74%) dogs 6 
with IE and 292 (75.26%) age and breed matched control dogs met the inclusion criteria. 7 
Control dogs had significantly higher “Trainability” scores than dogs with IE (p=0.04). Post-IE, 8 
dogs had significantly higher “Dog-Directed Fear or Aggression” (p=0.02), “Non-Social Fear” 9 
(p=0.01), “Attachment/Attention-Seeking Behaviour” (p=0.04), “Attention-Deficit” (p=0.02) 10 
and significantly lower “Trainability” (p=0.02) than prior to the onset of IE. Medication status 11 
did not significantly affect any behavioural factor, but drug-resistant dogs had significantly 12 
less “Trainability” than drug-responsive (p=0.04) and partially drug-responsive dogs (p=0.03). 13 
Behavioural differences related to cognitive function are seen between dogs with IE and 14 
controls. Behavioural changes related to anxiety, attention and cognition are seen in dogs 15 
following the onset of IE. The ability to clinically define and diagnose behavioural 16 
comorbidities in dogs is much needed from both a clinical and research perspective. 17 
  18 
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Introduction 19 
Psychological and neurodevelopmental comorbidities are reported to effect up to 50% 20 
of people with epilepsy1–5, alongside neuropsychiatric and cognition impairments6. These 21 
comorbidities can have a drastic negative effect on health-related quality of life (QoL), 22 
sometimes more so than seizure frequency7–12. Carer-perceived QoL of a dog with idiopathic 23 
epilepsy (IE) is associated with the carers own QoL13, and seizure activity can increase carer 24 
stress14. Breed-specific studies have reported behavioural changes in dogs with IE15–17.  Larger 25 
studies have shown differences in behaviour of dogs pre- and post-onset of IE and between 26 
dogs with IE and controls18–20. Similar studies have used the Canine Behavioural Assessment 27 
and Research Questionnaire (CBARQ) but did not use the standard method for analysis19. 28 
Using the established tool and analysis method would allow more comparability between 29 
studies. A cross-sectional case-control questionnaire study was carried out with the aim to 30 
increase and strengthen the existing evidence base.  31 
 32 
Method 33 
Research was approved by the RVC animal and welfare ethical review board (URN 34 
M2015 0053). Owners of eight breeds of dog previously identified to be at increased risk of 35 
IE compared to cross breeds (Golden Retriever, Labrador, Cocker Spaniel, Border Terrier, 36 
German Shepherd Dog, Parson Jack Russell Terrier, Boxer, and Border Collie)21 were 37 
recruited. Dogs aged between 6 months and 10 years old without neurological disease, 38 
aside IE were eligible for inclusion. Owners were recruited via social media to complete an 39 
online questionnaire containing two previously validated behavioural questionnaires 40 
(Appendix 1); the C-BARQ22 and Dog-ADHD23 rating scale in regards of their dogs’ behaviour; 41 
current behaviour only for the controls, and behaviour both current and prior to onset of IE 42 
for the dogs with IE. Medication information, such as medications taken and change in 43 
seizure frequency on them, was collected to allow for allocation of drug-responsive, 44 
partially drug-responsive and drug-resistant categories24. 45 
Statistical analysis was carried out on IBM Statistical Package for the Social Sciences 46 
(SPSS) Version 23. Dogs were matched for age and breed. A mean score was calculated for 47 
each behavioural factor. Normality was assessed statistically, and the appropriate statistical 48 
test was utilised accordingly to compare groups such as control behaviour vs. current IE 49 
group behaviour, or behaviour of sub-categories of dogs with IE, e.g. medication status. All 50 
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p-values were False Discovery Rate (FDR) correcteda.  General Linear Mixed Models (GLMM) 51 
for binary outcomes using backwards selection were applied following univariate analyses 52 
to identify variables liberally associated (p<0.1) with the study group.  53 
 54 
Results 55 
Of 834 responses, 388 dogs were included; 96 (24.74%) with IE and 292 (75.26%) 56 
controls. Responses were excluded if they did not meet inclusion criteria, were incomplete, 57 
or to allow for matching. Average time since onset of IE was 32 months (range: 0-111 58 
months). Controls had a significantly higher “Trainability” score, compared to the current IE 59 
group scores (p=0.04). Dogs with IE received significantly higher post-onset CBARQ scores 60 
for “Dog-Directed Fear or Aggression” (p=0.02), “Non-Social Fear” (p=0.01), 61 
“Attachment/Attention-Seeking Behaviour” (p=0.04), “Attention-Deficit” (p=0.02) and 62 
significantly lower “Trainability” (p=0.02) than prior to the onset of IE (Figure 1, Table 1).  In 63 
a GLMM, these behavioural factors were not affected by other variables tested (e.g. age, 64 
seizure frequency, cluster seizures).  65 
Twelve dogs (12.50%) were drug-naïve, 44 (45.83%) were receiving monotherapy 66 
and 40 (41.67%) were receiving polytherapy. Owner-reported medication status did not 67 
significantly affect any behavioural factor. Excluding drug-naïve dogs and dogs whose 68 
owners could not recall specific medication information; 21 (32.8%) were drug-responsive, 69 
20 (31.3%) were partially drug-responsive and 23 (35.9%) were drug-resistant.  Drug-70 
resistant dogs had significantly less “Trainability” than drug-responsive (p=0.04) and 71 
partially drug-responsive dogs (p=0.03).  72 
 73 
Discussion 74 
Dogs with IE obtained significantly lower scores for "Trainability” than controls, 75 
similar to findings elsewhere15,25. Additionally, “Trainability” decreased following the onset 76 
of IE.  This may reflect an impairment in learning and/or memory, which could be due to 77 
progressive damage from seizure activity, due to effect of the AED, due to ADHD-like 78 
behaviour or due to broader cognitive deficits without specific comorbidities like ADHD4. 79 
Cognition is a concern in people with epilepsy26, and in dogs with IE27,28. Both Winter, et al. , 80 
                                                     
a http://www.sdmproject.com/utilities/?show=FDR  
Behavioural Changes in Dogs with Idiopathic Epilepsy 15/07/2019 
(2018)27and Packer, et al., (2018)28 showed increased canine cognitive dysfunction in dogs 81 
with IE compared to controls, but factors such as aetiology, progression and age of onset 82 
were different from classic canine cognitive dysfunction, suggesting a different aetiology in 83 
dogs with IE28. A decrease in “Trainability” may mirror reduced memory or learning abilities 84 
or early onset of canine cognitive dysfunction in the dogs in this study. Interestingly no 85 
effect from AEDs was found in this study or in Packer, et al., (2018)28. Though not the 86 
validated form of analysis, it may be pertinent to the reader to learn that changes in the 87 
pre- to post-onset “Trainability” C-BARQ scores were mostly impacted by reduced obeying 88 
of the sit command, reduced response to correction or punishment and increased 89 
distraction by sights, sounds and smells.  90 
Behavioural changes were seen in the dogs with IE compared to the same dogs pre-91 
IE onset, which can be categorised under anxious and attention-related behaviours, 92 
corroborating findings from other veterinary studies17–19, despite using a different patient 93 
cohort, a different sampling method and different questionnaire tool, thereby strengthening 94 
the conclusions made by all studies. 95 
In people, neurodevelopmental and psychiatric comorbidities have been found to 96 
have a bidirectional relationship with epilepsy26,29–32, likely due to shared pathophysiological 97 
pathways via the hippocampus, amygdala and neuronal pathways33–35. Anxiety disorders are 98 
common amongst the general human population, but prevalence is higher in people with 99 
epilepsy33. Similarly, increased incidence of ADHD is seen in people with epilepsy compared 100 
to the healthy population29. In people, both anxiety and ADHD have been shown to have a 101 
bidirectional relationship with epilepsy30,31,36.  102 
No behavioural differences were found between drug-naïve dogs and those treated 103 
with monotherapy or polytherapy, contrary to findings elsewhere17,25, potentially resulting 104 
from low numbers of drug-naïve dogs. Recent veterinary literature has discussed side 105 
effects of anti-epileptic drugs37, their effect on anxiety in dogs with epilepsy38,39 and use as 106 
anxiolytics40. Deciphering which behavioural changes are the result of a true comorbidity 107 
with epilepsy, and which are a consequence of medication is challenging10,11,41. Further 108 
prospective, longitudinal studies are required to untangle these effects in dogs with IE.  109 
Drug-resistant and partially drug-resistant dogs received significantly lower scores 110 
for the C-BARQ subscale "Trainability" than partially drug-responsive dogs.  Shihab, et al. 111 
(2011)18 classified dogs as drug-responders or drug non-responders and reported significant 112 
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changes in “controlling aggression”, “demented behaviour” and “abnormal perception”, the 113 
latter two potentially contributing to decreased “Trainability” seen here. The relationship 114 
between drug-resistance and behaviour is a contentious issue in human epilepsy research, 115 
which poses the question of whether it is a result of the initial epilepsy phenotype or due to 116 
progressive degeneration of the brain with ongoing seizures, with supportive evidence for 117 
both sides8,41–44. It remains unknown whether treating a comorbidity might improve a dog’s 118 
response to AEDs39, but it is important to consider that a drug-resistant dog may be more 119 
likely to exhibit clinical side-effects of medication thereby affecting a perceived behavioural 120 
difference17. A holistic approach, providing a considered and well-balanced treatment of the 121 
comorbidity alongside seizure frequency or intensity, should be adopted in such cases. 122 
Limitations of this study include owner-reported IE and normalcy, and potential for recall 123 
and population bias.  124 
 125 
Conclusion 126 
Behavioural differences related to cognitive function are seen between dogs with IE 127 
and controls, and behavioural changes related to anxiety, attention and cognition are seen 128 
in dogs following the onset of IE, which could impact QoL. This suggests shared semiology 129 
and pathologic mechanisms of disease with epilepsy in people and support the dog as a 130 
naturally occurring model of IE. The ability to clinically define and diagnose behavioural 131 
comorbidities in dogs is much needed from both a clinical and research perspective. Further 132 
work should investigate the effects of specific AED protocols on behaviour. 133 
 134 
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 170 
Figure 1: Mean score for each behavioural factor for dogs with IE and controls (A) and mean 171 
score for each behavioural factor for dogs pre- and post-onset of IE (B). * = p<0.05 172 
 173 
Table 1: Mean scores for each behavioural factor across each group, value and FDR-174 
corrected p-value. 175 
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Behavior 
Factor 
Control 
Mean (SD) 
Current IE 
Mean (SD) 
Z 
p  
(FDR corrected) 
Pre IE 
Mean (SD) 
Current IE 
Mean (SD) 
Z 
p  
(FDR corrected) 
Stranger 
Aggression 
0.807 
(0.871) 
0.759 
(0.898) 
-1.175 
0.240 
(0.360) 
0.654 
(0.819) 
0.783 
(0.950) 
-0.364 
0.716 
(0.859) 
Dog 
Aggression 
1.196 
(1.143) 
1.053 
(1.220) 
-1.568 
0.117 
(0.248) 
0.700 
(1.050) 
1.112 
(1.277) 
-2.284 
0.005 
(0.020)* 
Owner 
Aggression 
0.095 
(0.257) 
0.158 
(0.359) 
-1.977 
0.048 
(0.180) 
0.143 
(0.351) 
0.1308 
(0.299) 
-0.169 
0.866 
(0.945) 
Stranger 
Fear 
0.751 
(0.956) 
0.660 
(0.945) 
-0.840 
0.401 
(0.535) 
0.479 
(0.765) 
0.664 
(0.948) 
-1.387 
0.166 
(0.285) 
Non-Social 
Fear 
0.963 
(0.798) 
1.029 
(0.940) 
-0.284 
0.776 
(0.847) 
0.740 
(0.792) 
1.038 
(0.887) 
-3.380 
0.001 
(0.012)* 
Pain 
Sensitivity 
0.806 
(0.886) 
0.842 
(0.949) 
-0.423 
0.672 
(0.806) 
0.652 
(0.930) 
0.805 
(0.896) 
-2.110 
0.035 
(0.070) 
Separation 
0.220 
(0.453) 
0.357 
(0.660) 
-1.539 
0.124 
(0.248) 
0.351 
(0.747) 
0.357 
(0.689) 
-0.031 
0.975 
(0.975) 
Attachment 
1.875 
(0.855) 
2.078 
(0.754) 
-2.431 
0.015 
(0.090) 
1.960 
(0.852) 
2.077 
(0.788) 
2.402 
0.017 
(0.048)* 
Chasing 
2.000 
(1.012) 
1.789 
(1.106) 
-1.881 
0.060 
(0.180) 
0.784 
(1.095) 
1.856 
(1.114) 
0.749 
0.455 
(0.683) 
Excitable 
2.568 
(1.001) 
2.545 
(1.011) 
-0.174 
0.862 
(0.862) 
2.588 
(1.053) 
2.595 
(0.962) 
0.379 
0.705 
(0.859) 
Trainability 
2.961 
(0.537) 
2.762 
(0.636) 
-2.932 
0.003 
(0.036)* 
2.914 
(0.731) 
2.741 
(0.657) 
-2.821 
0.005 
(0.020)* 
Attention 
0.696 
(0.414) 
0.789 
(0.513) 
-1.350 
0.177 
(0.303) 
0.675 
(0.521) 
0.806 
(0.534) 
-2.685 
0.007 
(0.021)* 
Current IE = behavioural score for dogs with idiopathic epilepsy at present 176 
Pre IE = behavioural score for dogs with idiopathic epilepsy prior to the onset of seizure activity 177 
* denotes a statistically significant result following false discovery rate (FDR) processing 178 
 179 
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